With the advent of in vitro immunologic testing, we can now detect exposed individuals who
are sensitized to beryllium and those who have chronic beryllium disease (CBD) with lung …

Context Although chronic beryllium disease (CBD) is clearly an immune-mediated
granulomatous reaction to beryllium, acute beryllium disease (ABD) is commonly …

The clinical syndrome of chronic beryllium disease (CBD)" was first described in 1946 by
Hardy and Tab-ershaw (1). Seventeen fluorescent lamp workers presented with a syndrome …

Chronic beryllium disease (CBD) is one of two pulmonary syndromes caused by
environmental exposure to beryllium. Acute beryllium disease was first described in 1943 …

Chronic granulomatous lung disease caused by industrial exposure to beryllium continues
to occur, but no community cases have been reported in more than 30 yr. With the advent of …

Rationale: Beryllium continues to have a wide range of industrial applications. Exposure to
beryllium can lead to sensitization (BeS) and chronic beryllium disease (CBD). Objectives …

The blood beryllium lymphocyte proliferation test is used in medical surveillance to identify
both beryllium sensitization and chronic beryllium disease. Approximately 50% of …

We conducted a medical screening for beryllium disease of 577 former workers from a
beryllium processing facility. The screening included a medical and work history …

Chronic beryllium disease is predominantly a pulmonary granulomatosis that was originally
described in 1946. Symptoms usually include dyspnea and cough. Fever, anorexia, and …

Objective: People exposed to beryllium compounds are at increased risk of developing
beryllium sensitization and chronic beryllium disease (CBD). The purpose of this short …